{"disease":{"id":"c1-inhibitor-deficiency","name":"c1 inhibitor deficiency"},"drugs":{"marketed":[{"drug_id":"conestat-alfa","indication_name":"Hereditary C1 esterase inhibitor deficiency - deficient factor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ruconest","generic_name":"CONESTAT ALFA","company_name":"Pharming Group N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ruconest","indication_name":"Hereditary C1 esterase inhibitor deficiency - deficient factor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ruconest","company_name":"Bernstein Clinical Research Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06210698","title":"Angioedema Biomarker Research Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Foundation For Rare Disease Research","has_results":false},{"nct_id":"NCT06343779","title":"Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":false},{"nct_id":"NCT02892682","title":"The Role of the Coagulation Pathways in Recurrent Angioedema","phase":"NA","overall_status":"TERMINATED","enrollment_count":96,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04618211","title":"Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":true},{"nct_id":"NCT03029728","title":"Biomarker for Hereditary AngioEdema Disease","phase":"","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT05047185","title":"Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":false},{"nct_id":"NCT07448181","title":"Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Istituti Clinici Scientifici Maugeri SpA","has_results":false},{"nct_id":"NCT07046806","title":"Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute for Asthma and Allergy","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}